Endo Pharmaceuticals (NASDAQ: ENDP) was downgraded by TheStreet from a “buy” rating to a “hold” rating in a research note issued on Monday.
The analysts wrote, “Endo Health Solutions (ENDP) has been downgraded by TheStreet Ratings from buy to hold. The company’s strengths can be seen in multiple areas, such as its good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity.”
A number of other analysts have also recently weighed in on ENDP. Analysts at Piper Jaffray downgraded shares of Endo Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research note to investors on Monday, February 25th. They now have a $22.00 price target on the stock, down previously from $28.00. Separately, analysts at RBC Capital downgraded shares of Endo Pharmaceuticals from a “sector perform” rating to an “underperform” rating in a research note to investors on Thursday, February 7th. They now have a $24.00 price target on the stock, down previously from $25.00. Finally, analysts at Needham & Company reiterated an “underperform” rating on shares of Endo Pharmaceuticals in a research note to investors on Thursday, January 31st.
Nine research analysts have rated the stock with a buy rating, nine have given a hold rating, one has given an underweight rating, and two have given a sell rating to the company’s stock. The company presently has an average rating of “overweight” and an average price target of $33.08.
Shares of Endo Pharmaceuticals opened at 30.02 on Monday. Endo Pharmaceuticals has a one year low of $25.01 and a one year high of $39.29. The stock’s 50-day moving average is currently $29.01. The company’s market cap is $3.387 billion.
Endo Pharmaceuticals last released its earnings data on Thursday, February 28th. The company reported $1.62 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.54 by $0.08. The company had revenue of $801.06 million for the quarter, compared to the consensus estimate of $807.98 million. During the same quarter last year, the company posted $1.40 earnings per share. Endo Pharmaceuticals’s revenue was down .3% compared to the same quarter last year. Endo Pharmaceuticals has set its FY13 guidance at $4.40-4.70 EPS. On average, analysts predict that Endo Pharmaceuticals will post $4.55 earnings per share for the current fiscal year.
Endo Health Solutions Inc., formerly Endo Pharmaceuticals Holdings Inc., is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services.
To view TheStreet’s full report, visit www.thestreetratings.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.